Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 plus Enfortumab Vedotin in Advanced Urothelial Carcinoma
NCT06483334Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in urothelial carcinoma (UC), sponsored by Merck & Co.. Started Jul 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06483334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483334.